Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation
May 20th 2025New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).
Read More
FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis
May 20th 2025Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.
Read More
Female Patients With ILD Show Lower ICU Mortality Rates: Matthew Viggiano, MD
May 20th 2025Matthew Viggiano, MD, internal medicine resident, Temple University Hospital, shares findings on a study in which female patients with interstitial lung disease (ILD) admitted to the intensive care unit (ICU) experienced significantly lower mortality rates and shorter hospital stays than male patients with ILD.
Read More
Improving Pulmonary Embolism Outcomes in Intermediate-Risk Patients: Krunal Patel, MD
May 20th 2025Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital, discusses how early intervention within 12 hours improved hemodynamic measurements and clinical outcomes in patients with pulmonary embolism.
Read More
Ensifentrine Shows Promise as Add-On, Stand-Alone Therapy in COPD: M. Bradley Drummond, MD, MHS
May 19th 2025M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive pulmonary disease (COPD) control.
Read More
Nerandomilast Slows Lung Function Decline in Patients With IPF
May 19th 2025The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.
Read More
Sleep Patterns, Predictors, and Pharmacologic Interventions in the ICU
May 19th 2025Research presented at the American Thoracic Society (ATS) 2025 International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the intensive care unit (ICU).
Read More
Improving COPD Trial Efficiency Using the Win Ratio: Sanjay Ramakrishnan, MD
May 19th 2025Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD).
Read More
The Impact of Wildfire Smoke on Rising Hospital Admissions: Michael Goulet, DO
May 18th 2025Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital, shares findings on the impact of wildfire smoke on hospital admissions and health care utilization in the Northeast.
Read More
Advancements in Asthma Treatment: Next Steps and Insights From Clinical Development of Rilzabrutinib
August 1st 2024Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.
Read More
Dr Paul Frohna Details Plans for Further Research on ENV-101 for IPF
June 24th 2024The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.
Read More
Dr Surya Bhatt Highlights NOTUS Trial Findings, Promising Dupilumab Results
June 1st 2024Surya Bhatt, MD, MSPH, of the University of Alabama at Birmingham, discussed the challenges of diagnosing chronic obstructive pulmonary disease (COPD) with type 2 inflammation, as well as the promising efficacy of dupilumab in treating this condition.
Read More
ATS 2024 Review: Innovative Treatments and Health Equity Take Center Stage
May 28th 2024Among the many topics discussed at the American Thoracic Society 2024 International Conference (ATS 2024), the majority touched on barriers to health equity and access, regardless of the key focus of each talk or study. Experts examined this within the field, emphasizing the importance of enhancing data diversity, modernizing diagnostic tools, and revising regulatory standards to promote equitable health outcomes for diverse populations.
Read More
Two abstracts presented at the American Thoracic Society 2024 International Conference analyzed the phase 3 LIBERTY COPD BOREAS trial, finding that dupilumab improves pre- and post-bronchodilator lung function measures in patients with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.
Read More
Experts Explore Barriers to Diversity in Respiratory Medicine Trials and Diagnostic Tools
May 22nd 2024In a scientific session at the American Thoracic Society (ATS) 2024 International Conference titled "An Inconvenient Truth: Health Disparities and Health Care Inequality in Respiratory Medicine," a number of experts discussed the various areas within the field that are impacted by disparities.
Read More
Dr Monica Kraft Reveals Link Between Preexisting Type 2 Inflammation, PASC Severity
May 22nd 2024Monica Kraft, MD, ATSF, contributed to research on preexisting asthma and the influence it may have on the severity of long-term COVID-19 symptoms, with some patients with asthma experiencing worse respiratory symptoms but better physical functioning compared with patients without asthma.
Read More
Dr Michael Arzt Analyzes ASV Therapy, Targets Treatment-Emergent Central Sleep Apnea With CVC
May 22nd 2024Michael Arzt, MD, investigated the use of ASV therapy in patients with TE-CSA and cardiovascular disease, finding it effective in reducing sleepiness and improving quality of life. It may be more suitable for some patients to be treated with ASV than CPAP due to its ability to automatically adjust pressure and potentially improve comfort.
Read More
Learning From Past Innovations to Advance Ventilation Use in Respiratory Conditions
May 21st 2024In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.
Read More
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More